{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:50:04Z","timestamp":1762249804972,"version":"build-2065373602"},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.thromres.2025.109444","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T07:03:52Z","timestamp":1756191832000},"page":"109444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A comprehensive review of the autoimmune pathogenesis of acquired hemophilia A"],"prefix":"10.1016","volume":"254","author":[{"given":"Jose","family":"Pardos-Gea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Barquinero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I\u00f1aki","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Cortina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris Garcia","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura Mart\u00edn","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.thromres.2025.109444_bb0005","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1538-7836.2012.04654.x","article-title":"Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"10","author":"Knoebl","year":"2012","journal-title":"J. Thromb. Haemost."},{"issue":"12","key":"10.1016\/j.thromres.2025.109444_bb0010","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1471-0528.2012.03469.x","article-title":"Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry","volume":"119","author":"Tengborn","year":"2012","journal-title":"BJOG"},{"issue":"7","key":"10.1016\/j.thromres.2025.109444_bb0015","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1182\/blood-2014-09-598268","article-title":"Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans","volume":"125","author":"Hofbauer","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109444_bb0020","first-page":"612","article-title":"Proceedings: a more uniform measurement of factor VIII inhibitors","volume":"34","author":"Kasper","year":"1975","journal-title":"Thromb. Diath. Haemorrh."},{"key":"10.1016\/j.thromres.2025.109444_bb0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0038-1653759","article-title":"The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability","volume":"73","author":"Verbruggen","year":"1995","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2025.109444_bb0030","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1172\/JCI105517","article-title":"The immunologic character of acquired inhibitors of antihemophilic globulin (factor 8) and the kinetics of their interaction with factor 8","volume":"46","author":"Shapiro","year":"1967","journal-title":"J. Clin. Invest."},{"issue":"3829","key":"10.1016\/j.thromres.2025.109444_bb0035","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1126\/science.160.3829.786","article-title":"Acquired factor 8 antibodies: further immunologic and electrophoretic studies","volume":"160","author":"Shapiro","year":"1968","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.thromres.2025.109444_bb0040","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-0038-1650189","article-title":"Acquired haemophilia: functional study of antibodies to Factor VIII","volume":"45","author":"Allain","year":"1981","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2025.109444_bb0045","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1182\/blood.V69.5.1475.1475","article-title":"FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting","volume":"69","author":"Fulcher","year":"1987","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.thromres.2025.109444_bb0050","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2012-07-444877","article-title":"Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients","volume":"121","author":"Whelan","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.thromres.2025.109444_bb0055","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1182\/blood-2008-08-174987","article-title":"Quantitation of anti-factor VIII antibodies in human plasma","volume":"113","author":"Krudysz-Amblo","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.thromres.2025.109444_bb0060","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1073\/pnas.89.9.3795","article-title":"Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals","volume":"89","author":"Algiman","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.thromres.2025.109444_bb0065","article-title":"The role of IgG4 in autoimmunity and rheumatic diseases","author":"Maslinska","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.thromres.2025.109444_bb0070","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.1985.tb02975.x","article-title":"IgA inhibitor to factor VIII\/von Willebrand factor","volume":"59","author":"Gralnick","year":"1985","journal-title":"Br. J. Haematol."},{"issue":"19","key":"10.1016\/j.thromres.2025.109444_bb0075","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood-2015-09-672774","article-title":"Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"127","author":"Tiede","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.thromres.2025.109444_bb0080","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood.V82.8.2452.2452","article-title":"Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction","volume":"82","author":"Gilles","year":"1993","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.thromres.2025.109444_bb0085","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.2016.148502","article-title":"The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells","volume":"102","author":"Gangadharan","year":"2017","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.thromres.2025.109444_bb0090","doi-asserted-by":"crossref","first-page":"7714","DOI":"10.4049\/jimmunol.180.11.7714","article-title":"Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia","volume":"180","author":"Wootla","year":"2008","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.thromres.2025.109444_bb0095","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2011.08890.x","article-title":"Do proteolytic antibodies complete the panoply of the autoimmune response in acquired haemophilia a?","volume":"156","author":"Mahendra","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"5992","key":"10.1016\/j.thromres.2025.109444_bb0100","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/312337a0","article-title":"Structure of human factor VIII","volume":"312","author":"Vehar","year":"1984","journal-title":"Nature"},{"issue":"27","key":"10.1016\/j.thromres.2025.109444_bb0105","doi-asserted-by":"crossref","first-page":"12574","DOI":"10.1016\/S0021-9258(18)67127-3","article-title":"The functional domains of coagulation factor VIII:C","volume":"261","author":"Burke","year":"1986","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.thromres.2025.109444_bb0110","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1532\/IJH97.05160","article-title":"Characterization of factor VIII inhibitors","volume":"83","author":"Shima","year":"2006","journal-title":"Int. J. Hematol."},{"issue":"5","key":"10.1016\/j.thromres.2025.109444_bb0115","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1182\/blood.V86.5.1811.bloodjournal8651811","article-title":"Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site","volume":"86","author":"Scandella","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109444_bb0120","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.V92.2.496","article-title":"Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor","volume":"92","author":"Jacquemin","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109444_bb0125","doi-asserted-by":"crossref","first-page":"7150","DOI":"10.1016\/S0021-9258(17)37260-5","article-title":"Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII","volume":"269","author":"Lenting","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.thromres.2025.109444_bb0130","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1365-2516.2010.02272.x","article-title":"Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A","volume":"16","author":"van Helden","year":"2010","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.thromres.2025.109444_bb0135","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1055\/s-0038-1648520","article-title":"A soluble recombinant factor VIII fragment containing the A2 domain binds to some human anti-factor VIII antibodies that are not detected by immunoblotting","volume":"67","author":"Scandella","year":"1992","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109444_bb0140","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1160\/TH02-09-0086","article-title":"Anti-heavy-chain monoclonal antibodies directed to the acidic regions of the factor VIII molecule inhibit the binding of factor VIII to phospholipids and von Willebrand factor","volume":"90","author":"Raut","year":"2003","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109444_bb0145","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1160\/TH06-09-0510","article-title":"Molecular characterization of human B domain-specific anti-factor VIII monoclonal antibodies generated in transgenic mice","volume":"98","author":"Lavigne-Lissalde","year":"2007","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2025.109444_bb0150","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2141.2011.08878.x","article-title":"Discontinuous epitopes on the C2 domain of coagulation factor VIII mapped by computer-designed synthetic peptides","volume":"155","author":"Lebreton","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"14","key":"10.1016\/j.thromres.2025.109444_bb0155","doi-asserted-by":"crossref","first-page":"9905","DOI":"10.1074\/jbc.M112.424564","article-title":"Characterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non-classical inhibitor antibodies","volume":"288","author":"Walter","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.thromres.2025.109444_bb0160","first-page":"197","article-title":"Structure of coagulation factor VIII bound to a patient-derived anti-C1 domain antibody inhibitor","volume":"142","author":"Childers","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.thromres.2025.109444_bb0165","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1182\/blood.V89.10.3663","article-title":"The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups","volume":"89","author":"Prescott","year":"1997","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2025.109444_bb0170","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000056708","article-title":"Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies","volume":"77","author":"Scandella","year":"1999","journal-title":"Vox Sang."},{"issue":"6","key":"10.1016\/j.thromres.2025.109444_bb0175","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0049-3848(01)00385-1","article-title":"Immunological characterization of factor VIII autoantibodies in patients with acquired hemophilia A in the presence or absence of underlying disease","volume":"104","author":"Matsumoto","year":"2001","journal-title":"Thromb. Res."},{"issue":"9","key":"10.1016\/j.thromres.2025.109444_bb0180","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/j.1538-7836.2012.04850.x","article-title":"The IgG autoimmune response in postpartum acquired hemophilia a targets mainly the A1a1 domain of FVIII","volume":"10","author":"Lapalud","year":"2012","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2025.109444_bb0185","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/MBC.0000000000000804","article-title":"Involvement of antifactor VIII autoantibodies specificity in the outcome of inhibitor eradication therapies in acquired hemophilia a patients","volume":"30","author":"Mingot-Castellano","year":"2019","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"4","key":"10.1016\/j.thromres.2025.109444_bb0190","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/jth.12846","article-title":"Anti-A2 and anti-A1 domain antibodies are potential predictors of immune tolerance induction outcome in children with hemophilia A","volume":"13","author":"Lapalud","year":"2015","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2025.109444_bb0195","doi-asserted-by":"crossref","first-page":"100020","DOI":"10.1016\/j.rpth.2022.100020","article-title":"Determinants of successful immune tolerance induction in hemophilia A: systematic review and meta-analysis","volume":"7","author":"Oomen","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109444_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1019275","article-title":"Hemophilia A patients with inhibitors: mechanistic insights and novel therapeutic implications","volume":"13","author":"Luo","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.thromres.2025.109444_bb0205","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.3389\/fimmu.2019.02991","article-title":"Tolerating factor VIII: recent progress","volume":"10","author":"Lacroix-Desmazes","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.thromres.2025.109444_bb0210","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1002\/1521-4141(200009)30:9<2548::AID-IMMU2548>3.0.CO;2-H","article-title":"Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and antifactor VIII inhibitor titer","volume":"30","author":"Qian","year":"2000","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.thromres.2025.109444_bb0215","first-page":"522","article-title":"Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site","volume":"92","author":"Pratt","year":"2004","journal-title":"Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2025.109444_bb0220","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1538-7836.2004.00850.x","article-title":"Epitope repertoire of human CD4(+) T cells on the A3 domain of coagulation factor VIII","volume":"2","author":"Reding","year":"2004","journal-title":"J. Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2025.109444_bb0225","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1046\/j.1538-7836.2003.00251.x","article-title":"Human CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII","volume":"1","author":"Reding","year":"2003","journal-title":"J. Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.thromres.2025.109444_bb0230","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/j.1538-7836.2004.00918.x","article-title":"T cell recognition of the A2 domain of coagulation factor VIII in hemophilia patients and healthy subjects","volume":"2","author":"Hu","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109444_bb0235","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1111\/j.1538-7836.2007.02762.x","article-title":"T-cell responses over time in a mild hemophilia A inhibitor subject: epitope identification and transient immunogenicity of the corresponding self-peptide","volume":"5","author":"James","year":"2007","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2025.109444_bb0240","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/j.1538-7836.2005.01309.x","article-title":"Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII","volume":"3","author":"Jones","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109444_bb0245","doi-asserted-by":"crossref","first-page":"1128641","DOI":"10.3389\/fimmu.2023.1128641","article-title":"Hemophilia A subjects with an intron-22 gene inversion mutation show CD4+ T-effector responses to multiple epitopes in FVIII","volume":"14","author":"Gunasekera","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.thromres.2025.109444_bb0250","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2015-11-682468","article-title":"T cells from hemophilia A subjects recognize the same HLA-restricted FVIII epitope with a narrow TCR repertoire","volume":"128","author":"Ettinger","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109444_bb0255","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/icb.2016.25","article-title":"Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells","volume":"94","author":"Garnier","year":"2016","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.thromres.2025.109444_bb0260","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1182\/blood-2009-01-200725","article-title":"Lineages of human T-cell clones, including T helper 17\/T helper 1 cells, isolated at different stages of anti\u2013factor VIII immune responses","volume":"114","author":"Ettinger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109444_bb0265","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/bloodadvances.2017013482","article-title":"FVIII proteins with a modified immunodominant T-cell epitope exhibit reduced immunogenicity and normal FVIII activity","volume":"2","author":"Ettinger","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2025.109444_bb0270","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/jth.14647","article-title":"Quantitative HLA-class-II\/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemophilia A","volume":"18","author":"Diego","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109444_bb0275","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1074\/mcp.M110.002246","article-title":"HLA-DR-presented peptide repertoires derived from human monocyte-derived dendritic cells pulsed with blood coagulation factor VIII","volume":"10","author":"van Haren","year":"2011","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.thromres.2025.109444_bb0280","doi-asserted-by":"crossref","first-page":"1345195","DOI":"10.3389\/fimmu.2024.1345195","article-title":"The self-reactive FVIII T cell repertoire in healthy individuals relies on a short set of epitopes and public clonotypes","volume":"15","author":"Porcheddu","year":"2024","journal-title":"Front. Immunol."},{"issue":"21","key":"10.1016\/j.thromres.2025.109444_bb0285","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1182\/bloodadvances.2017008706","article-title":"CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise na\u00efve and memory cells","volume":"1","author":"Meunier","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2025.109444_bb0290","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/jha2.319","article-title":"CD4 regulatory and na\u00efve T cells specific for factor VIII stand vis-\u00e0-vis to balance the immune response in healthy individuals","volume":"2","author":"Salzmann-Manrique","year":"2021","journal-title":"eJHaem"},{"issue":"19","key":"10.1016\/j.thromres.2025.109444_bb0295","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1182\/blood-2009-06-228155","article-title":"CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice","volume":"114","author":"Miao","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.thromres.2025.109444_bb0300","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159925","article-title":"Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs","volume":"132","author":"Becker-Gotot","year":"2022","journal-title":"J. Clin. Invest."},{"issue":"102","key":"10.1016\/j.thromres.2025.109444_bb0305","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2516.2010.02226.x","article-title":"Role of anti-idiotypic antibodies in immune tolerance induction","volume":"16","author":"Gilles","year":"2010","journal-title":"Haemophilia"},{"issue":"5","key":"10.1016\/j.thromres.2025.109444_bb0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061120","article-title":"Phenotypes of allo- and autoimmune antibody responses to FVIII characterized by surface plasmon resonance","volume":"8","author":"Lewis","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.thromres.2025.109444_bb0315","series-title":"I35th Haemophilia Symposium","article-title":"Towards the detection of FVIII-specific memory B cells in hemophilia A patients with FVIII inhibitors","author":"Lang","year":"2006"},{"key":"10.1016\/j.thromres.2025.109444_bb0320","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1111\/j.1538-7836.2007.02736.x","article-title":"FVIII-specific memory B cells in patients with hemophilia A","volume":"5","author":"Van Helden","year":"2007","journal-title":"J. Thromb. Haemost."},{"issue":"102","key":"10.1016\/j.thromres.2025.109444_bb0325","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2516.2010.02215.x","article-title":"Factor VIII-specific B cell responses in haemophilia A patients with inhibitors","volume":"16","author":"van Helden","year":"2010","journal-title":"Haemophilia"},{"issue":"8","key":"10.1016\/j.thromres.2025.109444_bb0330","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142906","article-title":"B cell-activating factor modulates the factor VIII immune response in hemophilia A","volume":"131","author":"Doshi","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.thromres.2025.109444_bb0335","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6483490","article-title":"Serum TNF-\u03b1 level as a possible predictor of inhibitor levels in severe hemophilia A","volume":"2021","author":"Susanah","year":"2021","journal-title":"Biomed. Res. Int."},{"issue":"2","key":"10.1016\/j.thromres.2025.109444_bb0340","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1055\/s-0037-1612983","article-title":"Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIII","volume":"87","author":"Sasgary","year":"2002","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2025.109444_bb0345","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1160\/TH06-09-0519","article-title":"Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients","volume":"97","author":"Hu","year":"2007","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2025.109444_bb0350","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1016\/j.thromres.2011.06.032","article-title":"Reduced production of IFN-\u03b3 and LT-\u03b1 is associated with successful prednisone therapy in patients with acquired hemophilia A: a pilot study","volume":"128","author":"Krusse-Jarres","year":"2011","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.thromres.2025.109444_bb0355","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1084\/jem.20150888","article-title":"A novel human autoimmune syndrome caused by combined hypomorphic and activating mutations in ZAP-70","volume":"213","author":"Chan","year":"2016","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.thromres.2025.109444_bb0360","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.13058","article-title":"ZAP70, too little, too much can lead to autoimmunity","volume":"307","author":"Ashouri","year":"2022","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.thromres.2025.109444_bb0365","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1172\/JCI78087","article-title":"T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity","volume":"125","author":"Moulton","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.thromres.2025.109444_bb0370","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2516.2007.01618.x","article-title":"Increased frequency of the CTLA-4 49 A\/G polymorphism in patients with acquired haemophilia A compared to healthy controls","volume":"14","author":"Pavlova","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109444_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of CTLA-4: from mechanism to autoimmune diseases","volume":"14","author":"Hossen","year":"2023","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.thromres.2025.109444_bb0380","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/hae.14573","article-title":"CTLA4-Ig prevents development of neutralizing antibody formation after continuous treatment with human FVIII in HA rats","volume":"28","author":"\u00d8vlisen","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109444_bb0385","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2516.2008.01976.x","article-title":"HLA genotype in patients with acquired haemophilia A","volume":"16","author":"Pavlova","year":"2010","journal-title":"Haemophilia"},{"issue":"22","key":"10.1016\/j.thromres.2025.109444_bb0390","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216372","article-title":"Key genes of the immune system and predisposition to acquired hemophilia A: evidence from a Spanish cohort of 49 patients using next-generation sequencing","volume":"24","author":"Pardos-Gea","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.thromres.2025.109444_bb0395","article-title":"NK cells in autoimmune diseases: protective or pathogenic?","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.thromres.2025.109444_bb0400","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00277-009-0887-3","article-title":"Acquired haemophilia caused by non-haemophilic factor VIII gene variants","volume":"89","author":"Tiede","year":"2010","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.thromres.2025.109444_bb0405","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5045\/kjh.2011.46.1.49","article-title":"Identification of a shared F8 mutation in the Korean patients with acquired hemophilia A","volume":"46","author":"Hwang","year":"2011","journal-title":"Korean J. Hematol."},{"key":"10.1016\/j.thromres.2025.109444_bb0410","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00669","article-title":"Further evidence that microRNAs can play a role in hemophilia a disease manifestation: F8 gene downregulation by miR-19b-3p and miR-186-5p","volume":"8","author":"Jankowska","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.thromres.2025.109444_bb0415","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1111\/jth.14290","article-title":"Large-scale identification of functional microRNA targeting reveals cooperative regulation of the hemostatic system","volume":"16","author":"Nourse","year":"2018","journal-title":"J. Thromb. Haemost."},{"issue":"13","key":"10.1016\/j.thromres.2025.109444_bb0420","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/jcmm.17741","article-title":"RNA sequencing suggests that non-coding RNAs play a role in the development of acquired haemophilia","volume":"27","author":"Tigu","year":"2023","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.thromres.2025.109444_bb0425","first-page":"2057019","article-title":"Successful management of acquired hemophilia a associated with bullous pemphigoid: a case report and review of the literature","volume":"2017","author":"Binet","year":"2017","journal-title":"Case Rep. Hematol."},{"key":"10.1016\/j.thromres.2025.109444_bb0430","doi-asserted-by":"crossref","first-page":"1155181","DOI":"10.3389\/fimmu.2023.1155181","article-title":"Associations between bullous pemphigoid and hematological diseases: literature review on mechanistic connections and possible treatments","volume":"14","author":"Yang","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.thromres.2025.109444_bb0435","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5021\/ad.20.301","article-title":"Case report of a novel association between anti-p200 pemphigoid and acquired haemophilia A","volume":"35","author":"Koh","year":"2023","journal-title":"Ann. Dermatol."},{"key":"10.1016\/j.thromres.2025.109444_bb0440","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.cellimm.2018.01.008","article-title":"Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A","volume":"325","author":"Peyron","year":"2018","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.thromres.2025.109444_bb0445","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3324\/haematol.2018.188219","article-title":"Nlinked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice","volume":"103","author":"Lai","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2025.109444_bb0450","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00393","article-title":"Removal of mannose-ending glycan at Asn2118 abrogates FVIII presentation by human monocyte-derived dendritic cells","volume":"11","author":"Delignat","year":"2020","journal-title":"Front. Immunol."},{"issue":"14","key":"10.1016\/j.thromres.2025.109444_bb0455","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1182\/bloodadvances.2021005758","article-title":"Influence of N-glycosylation in the A and C domains on the immunogenicity of factor VIII","volume":"6","author":"Vander Kooi","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2025.109444_bb0460","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.thromres.2012.09.011","article-title":"Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII","volume":"131","author":"Kannicht","year":"2013","journal-title":"Thromb. Res."},{"issue":"3","key":"10.1016\/j.thromres.2025.109444_bb0465","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/jth.15616","article-title":"Removal of single-site N-linked glycans on factor VIII alters binding of domain-specific monoclonal antibodies","volume":"20","author":"Ito","year":"2022","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2025.109444_bb0470","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.blre.2017.07.001","article-title":"To serve and protect: the modulatory role of von Willebrand factor on factor VIII immunogenicity","volume":"31","author":"Hartholt","year":"2017","journal-title":"Blood Rev."},{"issue":"12","key":"10.1016\/j.thromres.2025.109444_bb0475","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/bloodadvances.2019001144","article-title":"Gut dysbiosis modulates the immune response to factor VIII in murine hemophilia A","volume":"4","author":"Tarrant","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2025.109444_bb0480","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.autrev.2010.05.013","article-title":"Idiotype, anti-idiotype network of autoantibodies. Pathogenetic considerations and clinical application","volume":"9","author":"Tzioufas","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.thromres.2025.109444_bb0485","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.4049\/jimmunol.155.5.2754","article-title":"Unmasking of antiribosomal P autoantibodies in healthy individuals","volume":"155","author":"Stafford","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.thromres.2025.109444_bb0490","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF03402155","article-title":"Unmasking the anti-La\/SSB response in sera from patients with Sjogren\u2019s syndrome by specific blocking of anti-idiotypic antibodies to La\/SSB antigenic determinants","volume":"8","author":"Routsias","year":"2002","journal-title":"Mol. Med."},{"key":"10.1016\/j.thromres.2025.109444_bb0495","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1073\/pnas.0800578105","article-title":"The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes","volume":"105","author":"Oak","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.thromres.2025.109444_bb0500","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/08916934.2012.659299","article-title":"Protective role of anti-idiotypic antibodies in autoimmunity\u2014lessons for type 1 diabetes","volume":"45","author":"Hampe","year":"2012","journal-title":"Autoimmunity"},{"key":"10.1016\/j.thromres.2025.109444_bb0505","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/BF00917123","article-title":"Antiidiotypic antibodies against antiDNA antibodies in sera of families of lupus patients","volume":"9","author":"Abdou","year":"1989","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.thromres.2025.109444_bb0510","first-page":"1075","article-title":"Active systemic lupus erythematosus is associated with depletion of the natural generic antiidiotype (anti-F(ab\u2019)2) system","volume":"22","author":"Williams","year":"1995","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.thromres.2025.109444_bb0515","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0896-8411(92)90153-H","article-title":"Analysis of anti-idiotypic antibodies against anti-microsomal antibodies in patients with thyroid autoimmunity","volume":"5","author":"Tandon","year":"1992","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.thromres.2025.109444_bb0520","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0896-8411(05)80011-3","article-title":"Evidence for a role of antiidiotypic antibodies in the induction of remission in graves\u2019 disease","volume":"3","author":"Paschke","year":"1990","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.thromres.2025.109444_bb0525","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0022-2143(03)00104-5","article-title":"Role of antiidiotypic antibodies on the clinical course of idiopathic thrombocytopenic purpura","volume":"142","author":"Mehta","year":"2003","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.thromres.2025.109444_bb0530","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/art.1780400118","article-title":"Incidence and disease associations of a proteinase 3-antineutrophil cytoplasmic antibody idiotype (5\/7 Id) whose antiidiotype inhibits proteinase 3-antineutrophil cytoplasmic antibody antigen binding activity","volume":"40","author":"Strunz","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.thromres.2025.109444_bb0535","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1172\/JCI117489","article-title":"Healthy subjects produce both antifactor VIII and specific anti-idiotypic Abs","volume":"94","author":"Gilles","year":"1994","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.thromres.2025.109444_bb0540","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1073\/pnas.84.3.828","article-title":"Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies","volume":"84","author":"Sultan","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.thromres.2025.109444_bb0545","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0896-8411(05)80020-4","article-title":"A monoclonal anti-idiotypic antibody against the antigen-combining site of anti-factor VIII autoantibodies defines and idiotope that is recognized by normal human polyspecific immunoglobulins for therapeutic use (IVIg)","volume":"3","author":"Dietrich","year":"1990","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.thromres.2025.109444_bb0550","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0140-6736(84)90701-3","article-title":"Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gamma-globulin","volume":"2","author":"Sultan","year":"1984","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.thromres.2025.109444_bb0555","first-page":"311","article-title":"Anti-idiotypes against autoantibodies and alloantibodies to VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins","volume":"74","author":"Rossi","year":"1988","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.thromres.2025.109444_bb0560","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1182\/blood-2003-07-2207","article-title":"In vivo neutralization of a C2 domain-specific human anti-Factor VIII inhibitor by an anti-idiotypic antibody","volume":"103","author":"Gilles","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109444_bb0565","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-3083.1988.tb01502.x","article-title":"Suppression of in vitro production of anti-U1-ribonucleoprotein antibody by monoclonal anti-idiotypic antibody to anti-U1-ribonucleoprotein antibody","volume":"28","author":"Koide","year":"1988","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.thromres.2025.109444_bb0570","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.imlet.2003.11.028","article-title":"Autonomous SHIP-dependent FcgammaR signaling in pre-B cells leads to inhibition of cell migration and induction of cell death","volume":"92","author":"Brauweiler","year":"2004","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.thromres.2025.109444_bb0575","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4049\/jimmunol.157.1.5","article-title":"Fc receptor off-signal in the B cell involves apoptosis","volume":"157","author":"Ashman","year":"1996","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.thromres.2025.109444_bb0580","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/hae.14692","article-title":"Drug-associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance database","volume":"29","author":"Konstantinov","year":"2023","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.thromres.2025.109444_bb0585","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1111\/hae.13499","article-title":"Diagnostic delay in acquired haemophilia: analysis of causes and consequences in a 20-year Spanish cohort","volume":"24","author":"Pardos-Gea","year":"2018","journal-title":"Haemophilia"},{"issue":"8","key":"10.1016\/j.thromres.2025.109444_bb0590","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","article-title":"Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of Alemtuzumab","volume":"74","author":"Baker","year":"2017","journal-title":"JAMA Neurol."},{"issue":"06","key":"10.1016\/j.thromres.2025.109444_bb0595","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1111\/hae.14107","article-title":"Acquired haemophilia a after alemtuzumab therapy","volume":"26","author":"Van der Zwan","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109444_bb0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102181","article-title":"Acquired hemophilia A and other autoimmune diseases after alemtuzumab therapy for multiple sclerosis: a report of two cases","volume":"44","author":"Comini-Frota","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"01","key":"10.1016\/j.thromres.2025.109444_bb0605","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/bjh.16644","article-title":"Acquired haemophilia A after alemtuzumab treatment of multiple sclerosis","volume":"190","author":"Brink","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2025.109444_bb0610","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.msard.2019.07.016","article-title":"B cell depletion therapy resulting in sustained remission of severe autoimmune complications following alemtuzumab treatment of multiple sclerosis","volume":"35","author":"Massey","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.thromres.2025.109444_bb0615","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.msard.2018.11.029","article-title":"Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: a case report","volume":"27","author":"Pisa","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.thromres.2025.109444_bb0620","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-226588","article-title":"Development of acquired haemophilia A in a patient treated with alemtuzumab for multiple sclerosis","volume":"2018","author":"Madeley","year":"2018","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.thromres.2025.109444_bb0625","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-223016","article-title":"Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis","volume":"2017","author":"McCaughan","year":"2017","journal-title":"BMJ Case Rep."},{"issue":"1","key":"10.1016\/j.thromres.2025.109444_bb0630","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40290-023-00508-5","article-title":"Rare immune-related adverse events (irAEs): approach to diagnosis and management","volume":"38","author":"Javaid","year":"2024","journal-title":"Pharm. Med."},{"issue":"5","key":"10.1016\/j.thromres.2025.109444_bb0635","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1111\/hae.14632","article-title":"Immune checkpoint inhibitor-induced acquired haemophilia: a pharmacovigilance analysis of the FDA adverse event reporting system","volume":"28","author":"Moore","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2025.109444_bb0640","doi-asserted-by":"crossref","first-page":"e560","DOI":"10.1016\/j.cllc.2019.06.022","article-title":"Acquired hemophilia A after Nivolumab therapy in a patient with metastatic squamous cell carcinoma of the lung successfully managed with rituximab","volume":"20","author":"Gokozan","year":"2019","journal-title":"Clin. Lung Cancer"},{"issue":"18","key":"10.1016\/j.thromres.2025.109444_bb0645","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1056\/NEJMc1110923","article-title":"Hemophilia A induced by ipilimumab","volume":"365","author":"Delyon","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.thromres.2025.109444_bb0650","article-title":"Acquired hemophilia a secondary to an immune checkpoint inhibitor: a case report","volume":"3","author":"Fletcher","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"issue":"12","key":"10.1016\/j.thromres.2025.109444_bb0655","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/j.jtho.2018.06.024","article-title":"Nivolumab-induced hemophilia A presenting as gastric ulcer bleeding in a patient with NSCLC","volume":"13","author":"Kato","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.thromres.2025.109444_bb0660","article-title":"A diagnostic of acquired hemophilia following PD1\/PDL1 inhibitors in advanced melanoma: the experience of two patients and a literature review","volume":"12","author":"Gidaro","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"7","key":"10.1016\/j.thromres.2025.109444_bb0665","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/MBC.0000000000001244","article-title":"Acquired bleeding disorders secondary to immune checkpoint inhibitors: a case report and systematic literature review","volume":"34","author":"Archibald","year":"2023","journal-title":"Blood Coagul. Fibrinol."},{"issue":"1","key":"10.1016\/j.thromres.2025.109444_bb0670","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40364-021-00314-8","article-title":"Risk factors for immune-related adverse events: what have we learned and what lies ahead?","volume":"9","author":"Liu","year":"2021","journal-title":"Biomark. Res."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938482500194X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004938482500194X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:38:12Z","timestamp":1762249092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004938482500194X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":134,"alternative-id":["S004938482500194X"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109444","relation":{},"ISSN":["0049-3848"],"issn-type":[{"type":"print","value":"0049-3848"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive review of the autoimmune pathogenesis of acquired hemophilia A","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109444","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109444"}}